Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | GLA | P06280 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | ATM | Q13315 | 2/20 | 0.48 |
| ▸ | PIM1 | P11309 | 7/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | BIRC5 | O15392 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2198100 | 0.89 | GLA (0.54) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL15492448 | 0.87 | ATM (0.64) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL2201226 | 0.85 | KDM4E (0.50) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL2203894 | 0.83 | KDR (0.53) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL2200660 | 0.82 | ATM (0.51) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL12430342 | 0.81 | KDM4E (0.40) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL2199168 | 0.81 | KDM4E (0.55) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL2201233 | 0.80 | GSTP1 (0.51) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL2202978 | 0.79 | PIM1 (0.50) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL2818322 | 0.78 | MET (0.71) | ATMPIM1BIRC5METKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1846402-B1 | 3-AMINO-PYRAZOLO[3,4B]PYRIDINES USED AS INHIBITORS OF PROTEIN TYROSINE KINASES FOR TREATING ANGIOGENIC, HYPERPROLIFERATIVE OR NEURODEGENERATIVE DISEASES | BAYER IP GMBH (DE) | 2014-02-26 | — | — | EP | disclosed |
| US-7977325-B2 | 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AG (DE) | 2011-07-12 | — | — | US | disclosed |
| US-7977325-B2 | 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AG (DE) | 2011-07-12 | — | — | US | disclosed |
| US-20090030010-A1 | 3-Amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents | GENESYS CLOUD SERVICES, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090030010-A1 | 3-Amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents | GENESYS CLOUD SERVICES, INC. | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030010-A1 | 3-Amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents | MAP4K2, ABL1, MAP4K3 | KDM4E 1340/4885ALDH1A1 2786/4885GLA 1658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.